Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

63234 1503498110HCLSReviewIndonesiaAugust2017.pdf
Energy Boardroom

Switzerland Pharma Report

December 2016

This report offers companies, investors, policymakers, and stakeholders crucial insight into Switzerland; a country  located at the heart of Europe, home to some of the world’s most important international health institutions as well as two of its largest pharmaceutical companies in Novartis and Roche, and with a number one ranking globally in terms of ease of doing business and innovation. Switzerland is truly a healthcare and life sciences powerhouse.

The report features in-depth exclusive interviews with leading figures from public institutions and private companies, comprehensive articles, and up-to-date facts and figures on the Swiss healthcare and pharma sectors.

want to know more?

contents

  • ACKNOWLEDGEMENTS
  • FOREWORDS
  • PREFACE
  • SNAPSHOT IN FIGURES
  • HEALTHCARE STRATEGY INTERVIEW Pascal Strupler, Federal Office of Public Health
  • R&D INTERVIEW Walter Steinlin, CTI
  • MAPPING SWISS PHARMA FEATURE Basel, Zurich, Geneva and Zug
  • A NATIONAL CHAMPION INTERVIEW Dr. Oliver Bleck, Roche
  • THE ASSOCIATION VIEW INTERVIEW Walter P. Hölzle, vips
  • ROLL OF THE DICE FEATURE Enforcing Transparency
  • A SWISS SUCCESS STORY FEATURE Dr. Jean-Paul Clozel, Actelion
  • PATIENT-CENTRICITY INTERVIEW Tuomo Pätsi, Celgene
  • THERAPEUTIC AREAS FEATURE Emerging Trends
  • TROPICAL DISEASES AND PUBLIC HEALTH INTERVIEW Prof. Jürg Utzinger, Swiss Tropical and Public Health Institute

COVER STORY

A LEADER AMONG GIANTS

  1. Europe's Brain
  2. Hotbed of Innovation
  3. Where Academia and Business Acumen Collide
  4. Nurturing Scientific Advancement
  5. Rallying Against the 'Cancer Epidemic'
  6. Manufacturing Prowess
  7. Minnow in Volume, Colossus in Value
  8. Unorthodoxy Rules
  9. The Vaccination Anomaly
  10. Swiss Exceptional-ism
  11. Lifting the Lid on a Billion Dollar Investment
  12. Generics: Beginning to Take Off
  13. Growth Spots and Niches
  14. Pathway to Synergy
  15. Fly in the Ointment
  16. Market Entry by Proxy
  17. Consensus-Driven Culture
  • EMERGING MARKET INVESTMENT INTERVIEW Jean-Daniel Gerber, SIFEM
  • SME STRATEGY INTERVIEW Kari Sarvanto, Primex Pharmaceuticals

featuring

  • Pascal Strupler Federal Office of Public Health
  • Walter Steinlin Federal Commission of Technology and Innovation (CTI)
  • Walter P. Hölzle vips
  • Dr. Jean-Paul Clozel Actelion
  • Tuomo Pätsi Celgene
  • Prof. Jürg Utzinger Swiss Tropical and Public Health Institute
  • Jean-Daniel Gerber SIFEM
  • Kari Sarvanto Primex

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: